Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medications (metformin and a sulfonylurea) throughout the study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• Subjects with Type 2 diabetes mellitus

• Treated with both metformin and a sulfonylurea at defined doses for at least 3 months prior to screening

• BMI= 27-45 kg/m2

• HbA1c value between 7.5% and 11%

Exclusion Criteria:

• Treated with oral anti-diabetic medications other than metformin and sulfonylurea within 3 months of screening

• Patients treated previously with AC2993

• Patients presently treated with insulin